Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer ...

Merck KGaA (Merck) has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire ...

Online retailer Temu — owned by PDD Holdings (PDD) — aims to raise prices amid tariffs, while Tesla (TSLA) raises its EV ...

FRANKFURT (REUTERS) -German healthcare and materials group Merck KGaA said on Monday it struck a deal to acquire U.S. biotech ...

Merck KGaA acquires SpringWorks Therapeutics for $3.9B to enhance its cancer drug portfolio, boosting revenue growth and ...

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

Merck KGaA, Darmstadt, Germany, a science and technology company, has entered into a definitive agreement to acquire ...

Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of ...

German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based ...